Human c-Kit/D816V & GFP Expressing Stable Ba/F3 Cell Line

Description

This cell line stably expresses GFP alongside human c-Kit/D816V. While loss-of-function mutations were found in defects relating to hematopoiesis, melanogenesis, and gametogenesis. c-Kit/D816V-Stable Ba/F3 cells with GNNK- isoform has D-to-V mutation at position 816, a common c-Kit mutation where there is a substitution of the aspartic acid residue at position 816 to a valine; resulting in receptor activation independent from the Src family kinase phosphorylation and ubiquitination. It has lower surface c-kit receptor expression and downstream biological responses compared to wild-type c-Kit. The GNNK- isoform is the outcome of the c-Kit gene alternative splicing sites, resulting in different isoforms of the tetrapeptide GNNK and is the main transcript found in human malignancies. The cells are resistant to Imatinib Gleevec , an inhibitor of the c-Kit juxtamembrane mutations, and are able to proliferate in the absence of the ligand SCF. The analogous mutations are closely related to tyrosine kinase Flt3 mutated at aspartic acid 835 found in acute myeloid leukemia patients. Together with the wild-type c-Kit stable Ba/F3 cells Cat. No. T3041 and T3042 , these cell lines are suitable for studies in drug discovery for mutations in the c-Kit receptor which are associated to oncogenic and other diseases.